Opinion|Videos|February 28, 2025
Frontline Treatment and Molecular Testing in Upper GI Cancer: Precision-Guided Therapy
Experts discuss frontline treatment options for advanced upper gastric adenocarcinoma, molecular testing methods, challenges encountered, and how test results influence the choice of systemic therapy for patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Before we dive in, could you briefly provide an overview of frontline treatment options for patients with advanced upper gastric adenocarcinoma?
- When do you perform molecular testing, and what choice of testing method do you use?
- What are some challenges that you have encountered?
- How do the results influence the choice of systemic therapy in this patient?
Advertisement
Related to this article
Phase 1a data in 16 patients with recurrent glioblastoma established a recommended dose for expansion of LP-184 for a planned phase 1b/2a combination trial.
The FDA set a June 25, 2027, PDUFA date for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy.
The FDA approved pimicotinib for TGCT based on phase 3 MANEUVER data showing durable responses and improved pain, stiffness, and function.
Real-world data showed a 68% 12-month high-grade recurrence-free survival rate with hyperthermic mitomycin C in patients with BCG-unresponsive NMIBC.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
The FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid tumors who may be eligible for pembrolizumab.
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
3
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
4
Top 3 Poster Takeaways in Liver Cancer Care From The Liver Meeting 2026
5